January 22, 2016

--(BUSINESS WIRE)-- (NYSE:OPK) announced today that , MD, Chief Executive Officer of its BioReference/GeneDx subsidiaries, will speak at this year's , . Dr. Grodman's Presentation, titled 'New Model of Clinical Genomics Collaboration', will highlight a unique partnership between GeneDx and health systems to provide a complete genomic solution that facilitates improved patient care, education, research opportunities and commercial R&D collaborations.

As part of the 'New Approaches in Cancer Dx' track, is scheduled to present on at in Track 3 of the conference. Details on his talk can be found at http://2016sv.pmwcintl.com/bio-marc-grodman.

is an independent conference, co-hosted with and UCSF, that brings together experts across healthcare and biotechnology sectors to help further the adoption of personalized medicine in the clinic. This year's conference will be held on through the 27 at the in .

About

is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes , the nation's third-largest clinical laboratory with a core genetic testing business and a 420-person sales force to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros®1 in-office immunoassay platform. Our pharmaceutical business features Rayaldee™, a treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency ( PDUFA date) and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner Tesaro, IV formulation in Phase 3). Our biologics business includes hGH-CTP, a once-weekly human growth hormone injection (in Phase 3 and partnered with Pfizer), and a long-acting Factor VIIa drug for hemophilia (entering Phase 2a). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information is available at www.opko.com.

About BioReference and GeneDx

GeneDx and its parent company are members of the (: OPK) group of companies. BioReference is the third largest clinical laboratory in the US and is a leader in technological innovation in the industry. GeneDx is a world leader in Genomics with an acknowledged expertise in rare and ultra rare genetic disorders, as well as one of the broadest menus of sequencing services available among commercial laboratories. GeneDx performs more clinical Whole Exome Sequencing tests than any other diagnostic lab in the world. The GeneDx mission is to make clinical testing affordable and available to people with rare genetic conditions and their families. GeneDx provides testing to patients and their families in more than 55 countries. To learn more, please visit www.bioreference.com and www.genedx.com.

View source version on businesswire.com :http://www.businesswire.com/news/home/20160122005245/en/

, 202-600-4558
cerickson@mww.com
or, 305-575-4100
Investor Relations
or
Media
, 212-223-0689
trooney@rooneyco.com
or, 212-223-4017
mjanic@rooneyco.com
or
Investors
LHA, 212-838-3777
afields@lhai.com
or, 310-691-7100
bvoss@lhai.com

Source:

News Provided by Acquire Media

Close window | Back to top

Opko Health Inc. issued this content on 2016-01-22 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 2016-01-22 13:40:26 UTC

Original Document: http://investor.opko.com/releasedetail.cfm?ReleaseID=951328